Heads Up: NanoViricides, Inc. (NYSE: NNVC) is Topping Our Pre-Market Watchlist Right Now

*Sponsored Krypton Street Announces NanoViricides, Inc. (NYSE: NNVC) As Its Next Potential Breakout Idea! And Here’s Why… Bullish Technical Signals Across All Major Moving Averages, Indicating Strong Momentum Potential. Low Float with Market Cap Under $17M and Less Than 14M Shares Available, Fueling Potential for Explosive Swings. Targets High-Value Markets—Exceeding $10B. Progress Toward FDA Submission with Positive Pre-IND Feedback and Ongoing Safety Studies. Keep Reading to See Why We Have All Eyes on NanoViricides, Inc. (NYSE: NNVC) This Morning… February 5, 2025 Dear Reader, We need to shift our focus to one of my favorite sectors after news broke about the discovery of a new vi-rus in the US, raising alarm over the potential for a global pan-dem-ic. As the world grapples with the ever-growing threat of emerging infectious diseases, the urgency to find solutions has never been more critical.  The Camp Hill vir-us, identified in shrews, belongs to the same family as the deadly Nipah vir-us and could potentially spill over from animals to humans.  With its ability to mutate and spread rapidly, the vir-us has sparked concerns about a global health threat that could rival past outbreaks. The rapid evolution of vir-uses—especially those spread through human contact, particularly from monkeys, and others transmitted by birds—has sparked widespread concern.  These vir-uses have the potential to cross borders quickly, threatening global populations.  At the forefront of this battle is NanoViricides, Inc. (NYSE: NNVC), a company making rapid strides with innovative anti-vir-al technologies. Positioned as a leader in the effort to safeguard global health, NanoViricides, Inc. (NYSE: NNVC) is focusing on some of the most dangerous and unpredictable Vir-al threats of our time, including those linked to animal-origin outbreaks. As of yesterday, NanoViricides, Inc. (NYSE: NNVC) was trending above its 5-Day moving average of $1.134 and the company was triggering 17 Bullish Signals on TradingView's technical analysis tool using the 15-minute time-frame, including the Momentum Indicator. With a market cap under $17M and fewer than 14M shares available to the public, NanoViricides, Inc. (NYSE: NNVC) operates with a tight structure that has historically fueled explosive growth potential. This relatively low number of shares in the float can amplify movements, making it an even more intriguing company to watch. With these promising technical signals, NanoViricides, Inc. (NYSE: NNVC) continues to position itself as a leader in the fight against emerging Vir-al threats. Keep reading to see why NanoViricides, Inc. (NYSE: NNVC) is topping our watchlist this morning… New Vir-al Outbreak Sparks Global Alarm—Additionally, NanoViricides, Inc. (NYSE: NNVC) Aims to Tackle Emerging Threat The World Health Organization’s declaration of a new Vir-al outbreak as a Public Health Emergency of International Concern underscores the urgency of the situation.  A particularly concerning variant of this vir-us has emerged, displaying heightened pathogenicity, particularly in children.  Unlike previous strains, this new variant is not only more transmissible but also deadlier, exacerbating the global health risk.  Despite widespread fear and global attention, there is currently no approved treatment to combat this form of the vir-us, especially in regions outside of its origin where the infection could spread further. This is where NanoViricides, Inc. (NYSE: NNVC) comes in.  The company is accelerating its efforts to fight this growing threat with an innovative treatment known as NV-387.  This dr-ug has shown remarkable potential in preclinical studies, setting the stage for its transition into Phase 2 clinical trials. These trials are expected to test NV-387’s safety and efficacy in human patients, particularly those affected by the latest variant of the animal-origin outbreak. NanoViricides, Inc. (NYSE: NNVC) Positioning Itself to Combat a Potential pan-dem-ic In addition to addressing the evolving Vir-al outbreak, NanoViricides, Inc. (NYSE: NNVC)  is positioning itself as a key player in the fight against another looming Vir-al threat: the potential pan-dem-ic caused by a deadly influenza strain transmitted by birds.  This particular vir-us, known for its alarming potential to cause widespread illness and death, has raised concerns due to its rapid mutation capabilities.  The World Health Organization (WHO) has highlighted genetic mutations in this vir-us that may reduce the effectiveness of current anti-vir-al treatments, such as Tamiflu and other neuraminidase inhibitors (NAIs).  As the vir-us evolves, traditional anti-vir-al treatments risk becoming ineffective. NanoViricides, Inc. (NYSE: NNVC)’s NV-387 stands out in this context, offering a promising solution to combat this ever-evolving Vir-al threat.  The dr-ug works by mimicking essential host-side features that the vir-us cannot change, ensuring that even as the vir-us mutates, NV-387 remains effective.  With its broad-spectrum anti-vir-al properties, NV-387 has demonstrated superior efficacy in preclinical studies, particularly against vir-uses like the bird-origin strain.  Unlike existing treatments, which are vulnerable to mutations, NV-387's ability to bind and neutralize the vir-us remains intact, making it a valuable tool in the fight against a potential pan-dem-ic. Anil R. Diwan, Ph.D., President and Executive Chairman of NanoViricides, has emphasized the strategic advantage of NV-387, stating, "This dr-ug puts us in a great position to be able to fight a pan-dem-ic should it happen." Phase 2 Clinical Trials: A Critical Step Forward The company is now ready to begin Phase 2 clinical trials for NV-387, with a focus on treating patients infected with the new variant of the animal-origin vir-us and expanding its use for respiratory vir-uses, including influenza and the bird-origin strain.  The trials will begin with dose escalation, helping researchers determine the most effective and safe dosage for patients.  Following this, NanoViricides, Inc. (NYSE: NNVC) plans to expand the study to a larger cohort, collecting comprehensive data on the dr-ug’s efficacy when compared to existing treatments. The timeline for the clinical trials is ambitious. While clinical trials of this nature typically span several months, NanoViricides, Inc. (NYSE: NNVC) is optimistic that the trials for NV-387 can be completed within the year.  If all goes as planned, the data analysis phase could wrap up by 2026, potentially bringing a life-saving anti-vir-al treatment to market in record time. With $10B Market Potential, NanoViricides, Inc. (NYSE: NNVC) Eyes Major Breakthrough NanoViricides, Inc. (NYSE: NNVC) is a leader in developing nanomedicine dr-ugs to target vir-uses using its nanoviricide® technology.  This technology mimics host cell receptors to trick vir-uses into binding to the nanoviricide, dismantling them and blocking reinfection, providing a more durable solution than traditional antibodies or vax's. Key points: FDA Progress: Moving toward FDA submission with positive feedback on its NV-HHV-101 dr-ug candidate for herpes vir-uses. Innovative Technology: Nanoviricides can target vir-uses even as they mutate, offering broad protection against Vir-al infections. Manufacturing Facility: The company owns a cGMP-certified facility in Shelton, CT, allowing it to produce dr-ugs in-house, saving time and costs. HerpeCide™ Program: Focused on treating shingles, cold sores, and genital ulcers, with an estimated market size exceeding $10B. Diverse Pipeline: dr-ugs in development for influenza, HIV, Dengue, and Ebola with promising animal model results. Strong IP Portfolio: Exclusive patents for its TheraCour® technology, securing competitive market space. NanoViricides, Inc. (NYSE: NNVC) is positioned for growth with its breakthrough technology, broad pipeline, and in-house manufacturing, making it a key player in the fight against Vir-al diseases. 7 Reasons Why NanoViricides, Inc. (NYSE: NNVC) Topping Our  Watchlist This Morning… 1. Bullish Technical Signals: NanoViricides, Inc. (NYSE: NNVC) has triggered Bullish across all major moving averages tracked by TradingView, including the 10-Day, 20-Day, 30-Day, 50-Day, 100-Day, and 200-Day averages. This suggests strong momentum and positive market sentiment. 2. Low Float: With a market cap under $17M and fewer than 14M shares available to the public, NanoViricides, Inc. (NYSE: NNVC) operates with a relatively tight share structure, which historically has fueled the potential for explosive movements. 3. Innovative Nanoviricide® Technology: The company uses its nanoviricide® technology, which effectively targets and dismantles vir-uses, even as they mutate. This approach provides broader and more durable protection compared to traditional anti-vir-al methods like antibodies and vax's. 4. In-House Manufacturing Facility: With a cGMP-certified manufacturing facility in Shelton, CT, NanoViricides can produce its anti-vir-al dr-ugs internally, which reduces reliance on external partners, saves time, and drives down costs. 5. Market Potential with HerpeCide™: The company's HerpeCide™ program targets high-value markets such as shingles, cold sores, and genital ulcers. The market potential for these treatments exceeds $10B, highlighting substantial upside for NanoViricides, Inc. (NYSE: NNVC). 6. Diverse Pipeline: NanoViricides, Inc. (NYSE: NNVC) is advancing a variety of anti-vir-al dr-ug candidates targeting diseases like influenza, HIV, Dengue, and Ebola, with promising results from animal studies. 7. Progress Toward FDA Submission: NV-HHV-101, the company's herpes treatment, is advancing toward FDA submission. Positive feedback on pre-IND applications and ongoing safety studies pave the way for clinical trials and potential commercialization. Consider Adding NanoViricides, Inc. (NYSE: NNVC) To Your Radar This Week… NanoViricides, Inc. (NYSE: NNVC) is positioning itself as a leading force in the fight against Vir-al infections with its cutting-edge nanoviricide® technology. With bullish signals across all major moving averages and a low float, the company is primed for potential market movement.  Its HerpeCide™ program, targeting high-value markets like shingles, cold sores, and genital ulcers, along with a diverse pipeline for diseases such as influenza, HIV, and Ebola, demonstrates its broad market potential. The company’s cGMP-certified manufacturing facility ensures efficiency and cost savings, while progress towards FDA submission for its NV-HHV-101 herpes treatment brings it closer to commercialization.  With these strong fundamentals, NanoViricides, Inc. (NYSE: NNVC) is a company to watch closely as it continues to advance in the biotech space. NanoViricides, Inc. (NYSE: NNVC) is at the top of our watchlist this morning. Remember, (NNVC) has less than 14M shares in the float which could lead to significant swings if demand begins to shift. We're up early watching (NNVC) right now. Consider taking a look at (NNVC) before the bell rings.  Also, keep a lookout for my next update. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 02/04/2025 and ending on 02/05/2025 to publicly disseminate information about (NNVC:US) via digital communications. Under this agreement, Media 1717 LLC has been paid an seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (NNVC:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/nnvc/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice